Agents that target microtubule (MT) dynamics have been used extensively for the treatment
of metastatic breast cancer (MBC). Among these agents are taxanes (solvent-based
paclitaxel [sb-paclitaxel], docetaxel, and nab-paclitaxel) and non-taxanes, such as eribulin
and ixabepilone. Although these agents have been approved for the treatment of MBC,
questions regarding the ideal agent, regimen (single agent vs. combination vs. sequential),
and schedule still remain. This systematic review examined pivotal trials for taxanes …